CYTR $0.31   View long term graphs

CytRx Corp. (NASDAQ: CYTR) is a biopharmaceutical research and development oncology company based in Los Angeles, California.

The CytRx oncology pipeline includes clinical trials involving their lead drug aldoxorubicin. Aldoxorubicin (formerly INNO-206) is a modified form of doxorubicin, the popular anthracycline chemotherapeutic agent known as "red death".

Anthracyclines are a class of drugs that are among the most commonly used agents in the treatment of cancer. Doxorubicin, the first anthracycline to gain approval, has demonstrated efficacy in a wide variety of cancers including breast cancer, lung cancer, sarcomas, and lymphomas. However, doxorubicin is associated with side effects such as myelosuppression, gastrointestinal disorders, mucositis, stomatitis, cumulative cardiotoxicity and extravasation.

CytRx plans to expand its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, based on novel linker technologies that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites.

The corporate website is http://www.cytrx.com/aldoxorubicin

Steven Arthur Kriegsman is the President and CEO.

Aldoxorubicin (formerly INNO-206) is a tumor-targeted doxorubicin conjugate. Specifically, it is the (6-Maleimidocaproyl) hydrazone of doxorubicin. Essentially, this chemical name describes doxorubicin (DOXO) attached to an acid sensitive linker (EMCH).

Completed preclinical and clinical trials (see below) indicate that this novel agent has attributes that improve on native doxorubicin including reduction of adverse events, improvement in efficacy and the ability to reach the tumor more quickly. CytRx holds the exclusive worldwide rights to aldoxorubicin.

In 2014 CytRx was involved in a stock promotion scheme, paying DreamTeamGroup US$65,000 to write at least 13 articles that appeared on Seeking Alpha, Forbes.com, Motley Fool, and Cheat Sheet. The articles carried no conflict of interest disclosure, and were reviewed and edited by CytRx management. The stock price doubled following the articles. The articles and author profile pages (including pseudonyms) were removed after investigation by CNNMoney. A class action lawsuit has been filed against CytRx.

The events leading to CytRx lawsuits were revealed by a Seeking Alpha author named Richard Pearson who was shorting the CytRx company stock and the "short attack" was revealed by another Seeking Alpha author PhD. who wrote about the science of aldoxorubicin and revealed the motives behind Richard Pearson's article to short the company's stock. The second Seeking Alpha article pointed to a financial motive for the negative article and that the author Richard Pearson took a short position in CytRx company stock 3 days before he published his article about CytRx. http://seekingalpha.com/instablog/4519051-nir-etkovitz/2756043-behind-the-short-are-investors-of-cytrx-that-shallow

Q reports

Period Date Adjusted Actuals EPS GAAP EPS


2016-07-12 Lower Price Target S&P Equity Research $1.04 to $0.75
2016-07-12 Lower Price Target FBR & Co Outperform $8.00 to $3.00
2016-06-08 Reiterated Rating Jefferies Group Hold
2016-06-08 Reiterated Rating FBR & Co. Buy $8.00
2016-06-08 Reiterated Rating FBR & Co Buy $8.00
2016-05-20 Reiterated Rating FBR & Co. Outperform $8.00
2016-04-23 Reiterated Rating HC Wainwright Buy $10.00
2016-04-18 Reiterated Rating Jefferies Group Hold
2016-03-28 Boost Price Target Aegis Buy $9.00 to $12.00
2016-03-15 Reiterated Rating FBR & Co. Outperform $8.00
2016-03-14 Reiterated Rating Jefferies Group Hold $3.00 to $2.50
2016-01-26 Reiterated Rating Aegis Buy
2016-01-07 Initiated Coverage Jefferies Group Hold
2015-11-06 Reiterated Rating Oppenheimer Outperform $10.00
2015-11-06 Reiterated Rating Oppenheimer Holdings Inc. Outperform $10.00
2015-08-05 Reiterated Rating Oppenheimer Buy $10.00
2015-05-22 Reiterated Rating Aegis Buy $6.00
2015-05-09 Reiterated Rating Oppenheimer Outperform $10.00
2015-05-04 Set Price Target FBR & Co. Buy $8.00
2015-04-21 Initiated Coverage FBR & Co. Outperform $8.00
2015-04-17 Initiated Coverage Oppenheimer Outperform $10.00
2015-01-20 Set Price Target Aegis Buy $12.00
2015-01-07 Reiterated Rating Aegis Buy
2014-08-07 Reiterated Rating Aegis Buy
2014-06-02 Reiterated Rating Aegis Buy
2014-05-05 Reiterated Rating Aegis Buy
2014-03-17 Reiterated Rating Aegis Buy
2014-02-18 Reiterated Rating Aegis Buy
2014-01-23 Reiterated Aegis Capital Buy $9 to $12
2014-01-23 Boost Price Target Aegis Buy $9.00 to $12.00
2014-01-08 Boost Price Target Aegis Positive $8.00 to $9.00
2013-12-12 Reiterated Aegis Capital Buy $7 to $8
2013-12-12 Boost Price Target Aegis Buy $7.00 to $8.00
2013-11-25 Reiterated Rating Aegis Buy
2013-09-30 Reiterated Rating Aegis Buy
2012-12-04 Initiated Aegis Capital Buy $8
2012-09-10 Initiated Rodman & Renshaw Mkt Outperform $7
2010-01-08 Initiated Roth Capital Buy $2
2009-12-03 Initiated Merriman Buy
2009-06-08 Initiated Rodman & Renshaw Mkt Outperform $2
2008-06-12 Initiated Brean Murray Buy $3
2008-01-23 Reiterated Broadpoint Capital Buy $8 to $6.50
2007-10-24 Initiated Broadpoint Capital Buy $8
2007-10-19 Initiated Oppenheimer Buy $6
2007-04-05 Downgrade Rodman & Renshaw Mkt Outperform to Mkt Perform
2016-07-12 Lower Price Target S&P Equity Research $1.04 to $0.75
2016-07-12 Lower Price Target FBR & Co Outperform $8.00 to $3.00
2016-06-08 Reiterated Rating Jefferies Group Hold
2016-06-08 Reiterated Rating FBR & Co. Buy $8.00
2016-06-08 Reiterated Rating FBR & Co Buy $8.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker


In CYTR 0 funds of 2210 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
Patterson Scott Bradford 8.21%  (4577605) CYTR /
KRIEGSMAN STEVEN A Chief Executive Officer 0.70%  (387597) CYTR / GALE /
LINK MAX 0.47%  (260305) ALXN / AMDA / BSTC / CLSN / CYTR / DSCO /
SELTER MARVIN R 0.45%  (253193) CYTR /
LEVITT DANIEL J Chief Medical Officer 0.29%  (161036) AQXP / CYTR /
Wennekamp Richard L. 0.21%  (116965) CYTR /
Levin Ben GC/VP Legal Affairs/Secy 0.06%  (33578) CYTR /
CALOZ JOHN Y Chief Financial Officer 0.06%  (31792) CYTR /